Virusreinigung und Formulierungsverfahren
Anmelder: GE Healthcare Bio-Sciences Corp., Xcellerex, Inc. 🇺🇸
Details
- Veröffentlichungs-Nr.
- EP2700711
- Aktenzeichen
- EP13181160
- Anmeldetag
- 21. August 2013
- Veröffentlichung
- 22. November 2017
- Erteilung
- 22. November 2017
- Rechtsraum
- EP
- IPC
- C12N7/02
Abstract
Disclosed herein is provided a virus purification and formulation process for purifying a flavivirus represented by one of a a Yellow Fever Virus, Japanese Encephalitis virus, Dengue virus, and West Nile virus . The highly purified flavivirus virus product is characterized as having a low level of sucrose without significant virus loss such as that which is typically encountered by prior art virus purification processes. The disclosed process captures and purifies the virus, separating it from the host cell proteins and DNA, and leaving the host cell proteins and DNA behind. The process also can be used to inactivate and/or concentrate the virus sufficiently for use in formulations.
Anmelder
- Firmen
- GE Healthcare Bio-Sciences Corp.
Xcellerex, Inc. - Land
- 🇺🇸 USA
Schwedisches Life-Science-Unternehmen (früheres Amersham/Pharmacia Biotech, Sitz Uppsala) für Laborgeräte, Chromatographie und Bioprozesstechnik, ehemals Teil von GE Healthcare. Firmierte nach der Übernahme durch Danaher als Cytiva um.
708 Patente in unserer Datenbank
Fachgebiete
-
Stavbom, Ellen Elisabet
NoneStockholm